Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
FDA Tobacco Products Scientific Advisory Committee to hold a meeting » 08:25
02/14/20
02/14
08:25
02/14/20
08:25
XXII

22nd Century

$1.12 /

+0.02 (+1.82%)

The Committee discusses…

The Committee discusses 22nd Century Group's modified risk tobacco product applications for the following combusted filtered cigarette tobacco products: MR0000159: VLNTM King and MR0000160: VLNTM Menthol King in a meeting being held at FDA Silver Spring, MD on February 14 at 8:30 am. Webcast Link

ShowHide Related Items >><<
Conference/Events
FDA Tobacco Products Scientific Advisory Committee to hold a meeting » 07:59
02/14/20
02/14
07:59
02/14/20
07:59
XXII

22nd Century

$1.12 /

+0.02 (+1.82%)

The Committee discusses…

The Committee discusses 22nd Century Group's modified risk tobacco product applications for the following combusted filtered cigarette tobacco products: MR0000159: VLNTM King and MR0000160: VLNTM Menthol King in a meeting being held at FDA Silver Spring, MD on February 14 at 8:30 am. Webcast Link

ShowHide Related Items >><<
Hot Stocks
FDA panel finds 22nd Century claims substantiated in nicotine application » 11:32
02/12/20
02/12
11:32
02/12/20
11:32
XXII

22nd Century

$1.00 /

-0.005 (-0.50%)

The FDA's Tobacco…

The FDA's Tobacco Product Scientific Advisory Committee posted its briefing documents for 22nd Century Group's Modified Risk Tobacco Product application for its reduced nicotine content cigarettes. "FDA's preliminary scientific review of the application found that the three proposed claims are substantiated: there is about a 95% reduction in nicotine in the tobacco itself, the smoke it yields, and the nicotine that is absorbed when the product is smoked exclusively. When the product is dual used with normal nicotine content cigarettes, nicotine exposure is still significantly reduced. In studies of smokers who do not intend to quit, compared to smokers assigned to a control condition where they continue smoking usual brand cigarettes, smokers assigned to use the product reduce total number of cigarettes per day by about 30% at 6 weeks and 50% at 20 weeks." The FDA panel added, "Consumers understand the addiction risk of using the products relative to normal nicotine content cigarettes, but it is unclear whether they understand other relative health risks of using the products; they perceive the products to be lower risk than other cigarette...The proposed modified risk products can reduce dependence among individual tobacco users. The magnitude of the reduction in other morbidities and mortality from reduced dependence remains unclear...Nonsmokers have low intentions to use the products, and current smokers have moderate intentions to use the products." Shares of 22nd Century are up 3% to $1.04 ahead of Friday's committee meeting. Reference Link

ShowHide Related Items >><<
Hot Stocks
22nd Century to present MRTP application to FDA advisors on February 14 » 13:39
02/11/20
02/11
13:39
02/11/20
13:39
XXII

22nd Century

$0.94 /

+0.0007 (+0.07%)

22nd Century Group…

22nd Century Group announced that it will present the company's Modified Risk Tobacco Product, or MRTP, application for its reduced nicotine content cigarettes to the U.S. Food and Drug Administration's Tobacco Product Scientific Advisory Committee on Friday, February 14. "This meeting will be the first TPSAC meeting to review a combustible tobacco product application, and the first time it has reviewed a modified exposure claim application. Committee experts from across public health and medicine will hear from 22nd Century Group and the FDA about 22nd Century's MRTP application and will then discuss specific areas of interest to the FDA. The Company's MRTP applications seek a reduced exposure marketing authorization from the FDA to allow 22nd Century's reduced nicotine content cigarettes to be marketed under the brand name 'VLN' with pack and advertising claims stating that the cigarettes contain '95% Less Nicotine' than conventional tobacco cigarettes, as well as related claims," the company said. Mike Zercher, President of 22nd Century Group, added: "The presentation of our MRTP application to the FDA's Scientific Advisory Committee is yet another milestone in the company's mission to make available reduced nicotine content products to adult smokers."

ShowHide Related Items >><<
Options
Largest borrow rate increases among liquid names » 08:45
01/27/20
01/27
08:45
01/27/20
08:45
GTT

GTT Communications

$12.76 /

-0.31 (-2.37%)

, XXII

22nd Century

$1.06 /

-0.015 (-1.40%)

, WVE

Wave Life Sciences

$7.56 /

-0.27 (-3.45%)

, JCP

J.C. Penney

$0.79 /

-0.017 (-2.10%)

, BUD

AB InBev

$77.74 /

-0.47 (-0.60%)

, AGRX

Agile Therapeutics

$3.35 /

+0.27 (+8.78%)

, VBIV

VBI Vaccines

$1.27 /

-0.015 (-1.17%)

, SKT

Tanger Factory

$15.55 /

-0.835 (-5.10%)

, FRO

Frontline

$10.81 /

-0.47 (-4.17%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: GTT Communications (GTT) 70.19% +1.33, 22nd Century (XXII) 5.99% +0.32, WAVE Life Sciences (WVE) 2.78% +0.16, J C Penney (JCP) 5.31% +0.16, Anheuser Busch (BUD) 0.72% +0.13, Agile Therapeutics (AGRX) 2.45% +0.11, SPDR Euro STOXX (FEZ) 1.86% +0.11, VBI Vaccines (VBIV) 3.20% +0.10, Tanger Factory (SKT) 77.63% +0.10, and Frontline (FRO) 1.03% +0.07.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Hot Stocks
22nd Century trading resumes  15:49
12/23/19
12/23
15:49
12/23/19
15:49
XXII

22nd Century

$1.01 /

+ (+0.00%)

 
Hot Stocks
22nd Century to present modified risk tobacco product application to FDA » 15:41
12/23/19
12/23
15:41
12/23/19
15:41
XXII

22nd Century

$1.02 /

+0.005 (+0.50%)

22nd Century Group…

22nd Century Group announced that the U.S. Food and Drug Administration's Tobacco Products Scientific Advisory Committee will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group's Modified Risk Tobacco Product application for its VLNC cigarettes under the proposed brand name of VLN cigarettes. "We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN(R) cigarettes," said Michael Zercher, President and Chief Operating Officer of 22nd Century Group. "This public meeting is an important milestone for 22nd Century Group and for adult smokers who want to reduce their exposure to nicotine. We believe that the authorization of our MRTP application would support the FDA's goal to advance and implement a product standard to reduce the level of nicotine in all cigarettes sold in the U.S. to non-addictive levels. Authorization of our MRTP application for our proprietary VLN(R) cigarettes also would be further proof of the scientific and technical achievability of the FDA's proposed product standard to improve public health and save millions of lives."

Hot Stocks
22nd Century trading halted, news pending  15:37
12/23/19
12/23
15:37
12/23/19
15:37
XXII

22nd Century

$1.01 /

+ (+0.00%)

 
Hot Stocks
22nd Century jumps 24% after FDA allows sale of reduced nicotine cigarettes » 10:32
12/17/19
12/17
10:32
12/17/19
10:32
XXII

22nd Century

$0.84 /

+0.0024 (+0.29%)

22nd Century shares…

22nd Century shares jumped 20c, or 24%, to $1.02 and were halted for volatility following the FDA news.

Hot Stocks
FDA permits sale of two new 22nd Century reduced nicotine cigarettes » 10:30
12/17/19
12/17
10:30
12/17/19
10:30
XXII

22nd Century

$0.84 /

+0.0024 (+0.29%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration announced it has authorized the marketing of two new tobacco products manufactured by 22nd Century Group: Moonlight and Moonlight Menthol, which are combusted, filtered cigarettes that contain a reduced amount of nicotine compared to typical commercial cigarettes. "Following a rigorous science-based review of the premarket tobacco product applications (PMTAs) submitted by the company, the agency determined that authorizing these reduced nicotine products for sale in the U.S. is appropriate for the protection of the public health because of, among several key considerations, the potential to reduce nicotine dependence in addicted adult smokers, who may also benefit from decreasing nicotine exposure and cigarette consumption. The agency determined that non-smokers, including youth, are also unlikely to start using the products, and those who experiment are less likely to become addicted than people who experiment with conventional cigarettes. While today's action permits the new tobacco products to be legally sold or distributed in the U.S., it does not mean these products are safe or 'FDA-approved.' In its decision, the agency notes that the Moonlight and Moonlight Menthol cigarette products differ from conventional cigarettes in nicotine content only - the products share similar adverse health risks as conventional cigarettes. There are no safe tobacco products and those who do not use tobacco products should not start," the FDA stated in its approval announcement.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.